Anti-Inflammatory Drugs Market Size, Segmentations, Gross Margin and Segment Forecast 2021-2030
“Anti-inflammatory Drugs Market | Emerging Research »
The anti-inflammatory drugs market size reached USD 111.42 billion in 2021 and is expected to register a revenue CAGR of 9.3% during the forecast period
The Global Anti-Inflammatory Drugs Market The size reached USD 111.42 billion in 2021 and is expected to register a CAGR of 9.3% during the forecast period, according to the latest analysis from Emergen Research. The potential candidates in the pipeline are the main revenue growth driver of the market. For example, the monoclonal antibody mirikizumab (LY3074828) met the primary objectives and all important secondary objectives of the Phase 3 ulcerative colitis study LUCENT-1, according to a March announcement from Lilly. The drug’s potential as a treatment for moderate to severe ulcerative colitis was assessed throughout the 12-week multicenter induction phase. The humanized monoclonal antibody binds to the interleukin-23 p19 (IL-23p19) subunit. One cytokine that promotes inflammation is interleukin-23. In March, Lilly boasted that the Phase 3 LUCENT-1 trial, which used an anti-IL-23p19 monoclonal antibody, was the only one to show a reduction in bowel urgency in patients with moderate ulcerative colitis. to severe. Mirikizumab can be used to treat ulcerative colitis and Crohn’s disease, according to Lilly.
Get a sample report @ https://www.emergenresearch.com/request-sample/1299
Key Players profiled in the report are:
AbbVie Inc., Johnson & Johnson Private Limited, Bristol-Myers Squibb Company, Merck & Co., Inc., Pfizer Inc., Novartis AG, GSK plc, Lilly, Amgen Inc., Biogen
A recent trend in the market is the use of prodrug design. Nonsteroidal anti-inflammatory drugs (NSAIDs) are a class of drugs that are among the most frequently used, prescribed, and over-the-counter (OTC) medications for the treatment of inflammatory diseases. However, NSAIDs have several undesirable side effects, the most important of which are ulcerogenicity, mucosal hemorrhage, and gastritis. The majority of NSAID fragments are chemically made up of carboxylic functional groups, which may be one of the causes of mucosal damage. Prodrug design is one of the methods used to circumvent this problem. Thus, over the past decade, medicinal chemists have focused on the design and synthesis of NSAID prodrugs. The prodrug concept was developed to temporarily inhibit the free carboxylic group present in NSAIDs until systemic absorption.
Some highlights of the report
The anti-inflammatory biologics segment accounted for the largest share of revenue in 2021. Before the body senses or recognizes signs of inflammation, a number of metabolic steps take place. A biologic drug stops the inflammatory process in its tracks by directly targeting and inhibiting a specific reaction. Traditional medications, unlike biologics, only treat general inflammation once it has started (and accompanying symptoms, such as joint pain). When traditional NSAIDs (such as ibuprofen) or disease-modifying anti-rheumatic drugs (DMARDs) (such as methotrexate) are ineffective, patients with inflammatory autoimmune diseases, including rheumatoid arthritis and ankylosing spondylitis, may be prescribed biological drugs. In addition to these traditional medicines, biological products can be used. A biological target is categorized based on where the inflammation is in the process.
The injection segment accounted for the largest revenue share in 2021. The anti-inflammatory biologics market is expected to grow in revenue owing to the growing adoption of biologics. A special and effective type of medicine known as a biologic given by injection reduces or stops dangerous inflammation. Biologics and biosimilars are specialized classes of DMARDs. Usually they are recommended after conventional DMARDs have failed. These powerful drugs are very effective in treating many people with autoimmune and inflammatory arthritis, including rheumatoid arthritis (RA), psoriatic arthritis (PsA), and others. Since they are more difficult to produce than conventional DMARDs, they can be more expensive than most treatments an individual takes. While some medications can be given through self-administered injections, others require intravenous (IV) infusions done in a doctor’s office.
Request Report Discount @ https://www.emergenresearch.com/request-discount/1299
The autoimmune inflammatory disease segment accounted for the largest share of revenue in 2021. Increased incidence of psoriasis, inflammatory bowel disorders, and rheumatoid arthritis are contributing to the growth of this segment. Globally, the prevalence of RA between 1980 and 2019 was 460 per 100,000 people, with regional differences related to research design and location. According to the WHO, up to 14 million cases of rheumatoid arthritis may exist worldwide. Psoriasis affects people of all ages and from all countries. Psoriasis is estimated to affect between 0.09% and 11.43% of the world’s population, making it a serious global problem affecting at least 100 million people. The World Psoriasis Day Collaboration estimates that 125 million people worldwide, or 2-3% of the population, have psoriasis.
North America accounted for the largest revenue share in 2021, attributed to increased initiatives to refer patients to NSAIDs instead of opioids as they are addictive in this region. Dental pain is an example. Although nonsteroidal anti-inflammatory drugs (NSAIDs) are advised by the American Dental Association for pain management, opioids are still used more frequently than alternatives. However, more and more programs are launched to end this situation. Prescribed NSAIDs include Advil (ibuprofen), Aleve (naproxen), and Celebrex (celecoxib). However, Rochester dentists say that often an individual’s medical history makes it impossible to treat them with NSAIDs. Thereafter, they used a “multimodal” approach to pain management that included “NSAIDs, acetaminophen, and gabapentin.” This array of alternatives is meant to fill the void left when opioids are no longer used.
On August 18, 2022, Strides Pharma announced that the United States Food and Drug Administration (USFDA) had given its naproxen sodium softgels the green light. A nonsteroidal anti-inflammatory medicine called naproxen sodium capsules is used to treat pain or inflammation caused by conditions such as arthritis, ankylosing spondylitis, tendinitis, bursitis, gout, or menstrual cramps. Acute pain caused by other disorders can also be treated with it. Naproxen sodium soft gel capsules have an estimated US OTC market of $100 million.
Emergen Research has segmented the global anti-inflammatory drugs market based on drug class, route of administration, application, and region:
Drug Class Outlook (Revenue, USD Billion; 2019-2030)
Nonsteroidal anti-inflammatory drugs (NSAIDs)
Route of Administration Outlook (Revenue, USD Billion; 2019-2030)
To learn more about the report, visit @ https://www.emergenresearch.com/industry-report/anti-inflammatory-drugs-market
Application Outlook (Revenue, USD Billion; 2019-2030)
Autoimmune inflammatory diseases
Regional Outlook (Revenue, USD Billion; 2019-2030)
The rest of Europe
Rest of APAC
Rest of LATAM
Middle East and Africa
United Arab Emirates
Rest of MEA
Request report customization @ https://www.emergenresearch.com/request-for-customization/1299
Thank you for reading our report. Please contact us to learn more about the report or to request customization of the report. Our team will ensure that the report is best suited to your needs.
About Emergen Research
At Emergen Research, we believe in advancing with technology. We are a growing market strategy consulting and research firm with an extensive knowledge base on cutting-edge and potentially market-disrupting technologies that are expected to become more prevalent over the next decade.
Company Name: Emerging research
Contact person: Eric Lee
E-mail: Send an email
Call: +1 (604) 757-9756
Address:14671 110 Avenue Surrey, British Columbia, V3R2A9
State: British Columbia